WO1997041885A1 - Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets - Google Patents
Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets Download PDFInfo
- Publication number
- WO1997041885A1 WO1997041885A1 PCT/IB1997/000531 IB9700531W WO9741885A1 WO 1997041885 A1 WO1997041885 A1 WO 1997041885A1 IB 9700531 W IB9700531 W IB 9700531W WO 9741885 A1 WO9741885 A1 WO 9741885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferons
- interferon
- homeopathic
- arabic gum
- stabilised
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Definitions
- the invention concerns the stabilisation of interferons in aqueous solution for application in the manufacturing of sublingually administered tablets by homeopathic dilution method for the preventing and treating of interferon sensitive viral infections in humans and for functioning as an immunomodulator.
- Interferons belong to a group of glycoprotein and proteins and are derived from leukocytes, lymphoblastoid and fibroblast cells during the activation of immune responses in humans and other vertebrate animals or by recombinant DNA methods. Interferon is classified into alfa, beta and gamma designations which correspond to leukocyte, fibroblast and type II interferons, respectively.
- interferon For the sake of clarity, the various kinds of interferon would simply be referred to as "interferon" in the following description.
- PCT Patent Application WO 88/03441 is dealing with interferon therapy and may be considered as a good reference text to which one could report to become familiar with interferon and its use.
- interferon may be used in contact with oral or pharyngeal mucosa, for instance in a lozenge as a solid unitary dosage adapted to be dissolved in saliva when placed in the mouth.
- interferon which is commonly available in lyophilised form for application are highly hydrophobic and have to be stabilised in order to be kept, and used in homeopathic dosages. This is a key feature that seems to have been overlooked in the PCT Application cited above.
- An object of the present invention is therefore to provide stabilised interferon for homeopathic use and a method to stabilise interferon in order for this substance to be used in homeopathic dilutions.
- Another object of the invention is to use a viscous molecule having the general formula (C 5 H 10 O 5 ) n as a stabilising agent for stabilising interferon in homeopathic tablets.
- the method comprises adding a compound of the general formula (CsH Os),,. , to an aqueous solution of lyophilised interferons.
- arabic gum is a preferred compound.
- Another object of the invention is a pre-stabilised interferon and a method to pre-stabilise interferon before homeophatic dilutions by using albumin.
- This method comprises adding albumin as a previous pre-stabilising agent to an aqueous solution of lyophilised interferons.
- Another object of the invention is to use such stabilised interferons in homeopathic dilutions in a tablet or a pastille or granules which will be made in contact with saliva in a patient's mouth in order to enter the oral submucous lymphatic plexi.
- the present invention thus relates to a method of stabilising interferons in aqueous solution with a compound of the general formula (C 5 H 10 ⁇ 5 ) n such as arabic gum for the manufacture of sublingually administrated tablets in homeopathic concentrations.
- (C 5 H 10 O 5 ) n for instance arabic gum, will be used together with albumine as a pre-stabilisation agent and, in a preferred embodiment, various phosphates.
- Such stabilised interferon may be kept in solution under room temperature without the use of refrigeration up to 6 months to treat interferon sensitive viral infections and cancers.
- Said compound has to be used once the homeopathic dilutions have been carried out, and can be used as well earlier when preparing the base material which will be subjected to the homeophatic dilutions. In other words, this compound may be utilised twice successively during the manufacturing of the drug in its final form.
- the invention provides also a formulation for stabilising interferon for dissolution in aqueous alcohol solution.
- the invention further provides a method of applying the aqueous alcohol solution containing the aqueous alcohol solution containing interferon on a specially prepared excipient by homeopathic dilution procedure such as decimal homeopathic dilution procedure (DH) from 1x to 10x homeopathic concentrations (DH 1 to DH 10) for the manufacture of tablets.
- homeopathic dilution procedure such as decimal homeopathic dilution procedure (DH) from 1x to 10x homeopathic concentrations (DH 1 to DH 10) for the manufacture of tablets.
- This method of stabilisation can be applied to any kind of interferon like alfa, beta or gamma interferons derived from bovine and humans, or by recombinant DNA methods.
- interferons human alfa interferon is preferred.
- the invention relates also to a method for the preparation of an drug comprising an homeopathic amount of interferons , for instance from 1 I.U. to 2000 I.U. per 100 mg tablet, in which said tablet contains an excipient comprising a compound of general formula (C 5 H 10 O 5 ) n , such as arabic gum. Because of the homeopathic procedure, the above values of interferon from 1 I.U to 2000 I.U. are expressed in contents before dilutions.
- This tablet may also contain lactose and starch and is used to stimulate the therapeutic response in human patients by making contact with saliva in the patient's mouth.
- Interferon is a macromolecule which cannot pass through mucosae in general and mouth mucosa in particular. It will act by stimulating the immune system, by oral contact. Therefore, interferon contained in the tablets are likely not to enter the blood or lymphatic system of the patient. The tablets should preferably not be swallow as the interferon is likely to be destroyed in the stomach or the intestines and to become of no use.
- This tablet can be administrated sublingually for the prevention and treatment of various diseases such as hepatitis B+C, viral tumours and cancers, aids (HIV) and other viral infections sensitive to interferon treatment
- various diseases such as hepatitis B+C, viral tumours and cancers, aids (HIV) and other viral infections sensitive to interferon treatment
- a tablet of 100 mg comprising between 100 to 300 I.U. (as expressed before homeopathic dilutions) of stabilised human alfa-interferon will be administrated one to four times a day.
- a base material is prepared by dissolving lyophilised interferon in bidistilled water in the presence of lactose and by adding successively lyophilised albumin, sodium monohydrophosphate, sodium dihydrosulfate and (C 5 H 10 O 5 ) n , for instance arabic gum.
- this base material is subjected to a treatment of multidilutions as in the art in homeopathy, each time ten times (decimal dilutions) with an alcoholic aqueous solution.
- a typical treatment is fourth decimal treatment (DH 4).
- the alcoholic solution obtained is then sprayed on granules of excipient containing (C 5 H 10 O 5 ) n , for instance arabic gum, lactose and starch, and the mixture is vacuum dried and finally compressed into tablets.
- excipient containing (C 5 H 10 O 5 ) n , for instance arabic gum, lactose and starch
- a typical method of preparing tablets is given on the enclosed Table, which is an example of a homeopathic 4 DH dilution with corresponding typical weights, volumes and proportions to be used.
- the invention is carried out in three stages which are as follows :
- Base stock of 30 million I.U. of lyophilised high purity human alfa- interferon is thoroughly mixed with 20 ml of double distilled water, 20 g of lactose, 600 ⁇ g of lyophilised high purity (HP) albumin, 150 ⁇ g of sodium monohydrophosphate, 150 ⁇ g of sodium dihydrophosphate and 20 g of arabic gum to form the base material.
- the base material must be free of alcohol, and all ingredients are either of high purity or pharmaceutical grade.
- the base material is then dissolved under room temperature in 10 times of the weight of 20% aqueous ethyl alcohol solution for the first dilution step and is further carried out in steps 10 times of the weight of 20% aqueous ethyl alcohol solution repeatedly to the fourth step to give the final solution.
- This operation is carried out under standard homeophatic procedure.
- the excipient is prepared by mixing thoroughly 3000 g of arabic gum (20%); 4500 g of lactose (30%); and 7500g of wheat or rice starch, all pharmaceutical grade which become granular in texture.
- the final stock solution is then sprayed on the granules of the excipient with a regular spray nozzle used in homeopathic manufacture with sterilised, filtered air under one atmosphere pressure during less than 60 minutes while the entire mixture is being stirred by standard mixing procedures. Losses of stock solution vary between 5% and 50% depending on the equipment used. Tablets of 100 mg each containing 200 I.U. of stabilised human alfa-interferon are made by standard methods and vacuum dried at temperatures between 8 a C and 20 ⁇ C before packaging into blister packs.
- the tablets are to be used by patients sublingually to promote and enhance the immune response of the body for the treatment of viral infections sensitive to interferon.
- Excipient arabic gum, lactose, and starch for instance 20% arabic gum, 30% lactose, and 50% starch
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69715883T DE69715883T2 (en) | 1996-05-09 | 1997-05-09 | STABILIZATION OF INTERFERONES IN AQUEOUS SOLUTION BY RUBBER LAB |
EP97919596A EP0920329B1 (en) | 1996-05-09 | 1997-05-09 | Stabilization of interferons in aqueous solution by arabic gum |
DK97919596T DK0920329T3 (en) | 1996-05-09 | 1997-05-09 | Stabilization of interferons in aqueous solution with gum arabic |
AU24011/97A AU2401197A (en) | 1996-05-09 | 1997-05-09 | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets |
AT97919596T ATE224725T1 (en) | 1996-05-09 | 1997-05-09 | STABILIZATION OF INTERFERONS IN AQUEOUS SOLUTION USING RUBBER ARABIC |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB9600433 | 1996-05-09 | ||
CHPCT/IB96/00433 | 1996-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997041885A1 true WO1997041885A1 (en) | 1997-11-13 |
Family
ID=11004429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1997/000531 WO1997041885A1 (en) | 1996-05-09 | 1997-05-09 | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0920329B1 (en) |
AP (1) | AP1168A (en) |
AT (1) | ATE224725T1 (en) |
AU (1) | AU2401197A (en) |
DE (1) | DE69715883T2 (en) |
DK (1) | DK0920329T3 (en) |
ES (1) | ES2184084T3 (en) |
WO (1) | WO1997041885A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998051328A1 (en) * | 1997-05-09 | 1998-11-19 | Feronpatent Limited | Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets |
EP0950663A1 (en) * | 1997-08-01 | 1999-10-20 | Toray Industries, Inc. | Method for stabilizing useful proteins and useful protein compositions |
AP1168A (en) * | 1996-05-09 | 2003-06-30 | Feronpatent Ltd | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets. |
FR2836379A1 (en) * | 2002-02-28 | 2003-08-29 | Dit Bon Michel Betend | Supports for homeopathic allergen and antigen formulations containing quails' egg-white |
WO2005103067A1 (en) * | 2004-04-23 | 2005-11-03 | Novexin Limited | Methods and kits for stabilising, protecting and solubilising proteins |
JP2008501639A (en) * | 2004-04-23 | 2008-01-24 | ノベシン リミテッド | Methods and kits for stabilizing, protecting and solubilizing proteins |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH156609A (en) * | 1931-01-27 | 1932-08-15 | Chem Pharm Lab Bika V Poehlman | Method of making a dry, homeopathic remedy. |
WO1988003411A1 (en) * | 1986-11-06 | 1988-05-19 | Amarillo Cell Culture Company, Inc. | Improved interferon therapy |
EP0306423A1 (en) * | 1987-09-02 | 1989-03-08 | Medibrevex Sa | Galenical forms of theophylline for perlingual and sublingual administration |
EP0420049A1 (en) * | 1989-09-28 | 1991-04-03 | F. Hoffmann-La Roche Ag | Stabilized leucocyte-interferon |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123291A2 (en) * | 1983-04-20 | 1984-10-31 | Kyowa Hakko Kogyo Co., Ltd. | Method for stabilizing interferon |
EP0133767B1 (en) * | 1983-08-04 | 1991-04-03 | The Green Cross Corporation | Gamma interferon composition |
WO1997041885A1 (en) * | 1996-05-09 | 1997-11-13 | Feronpatent Limited | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets |
-
1997
- 1997-05-09 WO PCT/IB1997/000531 patent/WO1997041885A1/en active IP Right Grant
- 1997-05-09 AT AT97919596T patent/ATE224725T1/en not_active IP Right Cessation
- 1997-05-09 ES ES97919596T patent/ES2184084T3/en not_active Expired - Lifetime
- 1997-05-09 DE DE69715883T patent/DE69715883T2/en not_active Expired - Fee Related
- 1997-05-09 AU AU24011/97A patent/AU2401197A/en not_active Abandoned
- 1997-05-09 DK DK97919596T patent/DK0920329T3/en active
- 1997-05-09 EP EP97919596A patent/EP0920329B1/en not_active Expired - Lifetime
- 1997-05-09 AP APAP/P/1999/001682A patent/AP1168A/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH156609A (en) * | 1931-01-27 | 1932-08-15 | Chem Pharm Lab Bika V Poehlman | Method of making a dry, homeopathic remedy. |
WO1988003411A1 (en) * | 1986-11-06 | 1988-05-19 | Amarillo Cell Culture Company, Inc. | Improved interferon therapy |
EP0306423A1 (en) * | 1987-09-02 | 1989-03-08 | Medibrevex Sa | Galenical forms of theophylline for perlingual and sublingual administration |
EP0420049A1 (en) * | 1989-09-28 | 1991-04-03 | F. Hoffmann-La Roche Ag | Stabilized leucocyte-interferon |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
Non-Patent Citations (1)
Title |
---|
G. NETIEN ET AL.: "GALENICA", VOL. 16, "MEDICAMENTS HOMOPATHIQUES" 2nd. EDITION", 1986, TECHNIQUE ET DOCUMENTATION, PARIS, FR, XP002022482 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP1168A (en) * | 1996-05-09 | 2003-06-30 | Feronpatent Ltd | Stabilization of interferons in aqueous solution for manufacture of sublingually administered tablets. |
WO1998051328A1 (en) * | 1997-05-09 | 1998-11-19 | Feronpatent Limited | Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets |
EP0950663A1 (en) * | 1997-08-01 | 1999-10-20 | Toray Industries, Inc. | Method for stabilizing useful proteins and useful protein compositions |
US6391296B1 (en) | 1997-08-01 | 2002-05-21 | Toray Industries, Inc. | Method of stabilizing useful protein and useful protein compositions |
EP0950663A4 (en) * | 1997-08-01 | 2003-03-19 | Toray Industries | Method for stabilizing useful proteins and useful protein compositions |
FR2836379A1 (en) * | 2002-02-28 | 2003-08-29 | Dit Bon Michel Betend | Supports for homeopathic allergen and antigen formulations containing quails' egg-white |
EP1340493A1 (en) * | 2002-02-28 | 2003-09-03 | Betend-dit-Bon, Michel | Solid support for extemporaneous homeopathic medicine |
WO2005103067A1 (en) * | 2004-04-23 | 2005-11-03 | Novexin Limited | Methods and kits for stabilising, protecting and solubilising proteins |
JP2008501639A (en) * | 2004-04-23 | 2008-01-24 | ノベシン リミテッド | Methods and kits for stabilizing, protecting and solubilizing proteins |
AU2005235800B2 (en) * | 2004-04-23 | 2011-08-04 | Expedeon Limited | Methods and kits for stabilising, protecting and solubilising proteins |
Also Published As
Publication number | Publication date |
---|---|
EP0920329A1 (en) | 1999-06-09 |
DE69715883D1 (en) | 2002-10-31 |
ATE224725T1 (en) | 2002-10-15 |
EP0920329B1 (en) | 2002-09-25 |
DK0920329T3 (en) | 2003-01-27 |
AP1168A (en) | 2003-06-30 |
DE69715883T2 (en) | 2003-07-31 |
AU2401197A (en) | 1997-11-26 |
ES2184084T3 (en) | 2003-04-01 |
AP9901682A0 (en) | 1999-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3414539B2 (en) | Composition for nasal absorption | |
JPH07165613A (en) | Carrier for nasal absorption medicine and physiologically active peptide composition | |
EP0650354A1 (en) | Solid and liquid solutions of drugs which are not readily soluble in water | |
KR101564114B1 (en) | Oral administration of a calcitonin | |
DE69719083T2 (en) | Novel oral preparations of calcitonin | |
CA3162623A1 (en) | Aerosolization systems, methods, and apparatuses | |
WO2008137054A2 (en) | Composition for transmucosal delivery of polypeptides | |
JP2009544706A (en) | High dose orally soluble / degradable lyophilized dosage form | |
EP0920329B1 (en) | Stabilization of interferons in aqueous solution by arabic gum | |
JPH07118166A (en) | Insulin composition | |
JPH07118164A (en) | Carrier for nasal absorption agent and physiologically active peptide composition | |
CA2382887A1 (en) | Immunopotentiating compositions | |
AU730020B2 (en) | Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets | |
US6589559B1 (en) | Nasally administrable compositions | |
EP0588255A1 (en) | Physiologically active peptide compositions | |
EP0943336A1 (en) | Peptide-containing pharmaceutical compositions for oral administration | |
US7465711B2 (en) | Treatment of cancers of lymphocytic cells with product R | |
US5268169A (en) | Treatment method of ovarian cancer using interferon gamma | |
US20020107184A1 (en) | Method for treating melanoma | |
CN1193790C (en) | Thymosin composition injection and its prepn | |
JPH07118170A (en) | Carrier for nasal absorption agent, physiologically active peptide composition and their production | |
RU2245157C2 (en) | Biologically active additive for preventing and treating flu cases | |
RU2234939C1 (en) | Sublingual tablet medicinal preparation comprising alpha- interferon and method for its preparing | |
RU2201240C1 (en) | Method of panthohematogen-base preparations preparing | |
RU2141819C1 (en) | Ointment with human leukocytic interferon "interon" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997919596 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97539702 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997919596 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997919596 Country of ref document: EP |